EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Gentian Diagnostics AS's Enterprise Value is €46.54 Mil.
Gentian Diagnostics AS's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €1.01 Mil. Therefore, Gentian Diagnostics AS's EV-to-FCF for today is 45.90.
The historical rank and industry rank for Gentian Diagnostics AS's EV-to-FCF or its related term are showing as below:
FRA:6FK'
s EV-to-FCF Range Over the Past 10 Years
Min: -106.5 Med: -20.38 Max: 280.79
Current: 41.22
During the past 13 years, the highest EV-to-FCF of Gentian Diagnostics AS was 280.79. The lowest was -106.50. And the median was -20.38.
FRA:6FK's EV-to-FCF is ranked worse than 70.91% of 416
companies
in the Medical Devices & Instruments industry
Industry Median: 23.355
vs FRA:6FK: 41.22
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gentian Diagnostics AS (FRA:6FK) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gentian Diagnostics AS's PE Ratio (TTM) for today is calculated as:
Gentian Diagnostics AS's share price for today is €3.47.
Gentian Diagnostics AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.051.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Gentian Diagnostics AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gentian Diagnostics AS EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Gentian Diagnostics AS's EV-to-FCF falls into.
Gentian Diagnostics AS's current Enterprise Value is €46.54 Mil.
Gentian Diagnostics AS's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gentian Diagnostics AS (FRA:6FK) has a EV-to-FCF of 45.90 as of Jul. 12, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Gentian Diagnostics AS and its competitors. According to the industry distribution chart, Gentian Diagnostics AS ranks #295 out of 416 companies in the Medical Devices & Instruments industry, placing it in the top 70.9%.
Is Gentian Diagnostics AS's EV-to-FCF too high?
Gentian Diagnostics AS's current EV-to-FCF is 45.90. The Medical Devices & Instruments industry median EV-to-FCF is 23.36. Gentian Diagnostics AS's value of 45.90 is 96.5% above this industry median. Based on the distribution chart, Gentian Diagnostics AS ranks #295 out of 416 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Gentian Diagnostics AS has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gentian Diagnostics AS ranks #295 out of 416 companies for EV-to-FCF. This places Gentian Diagnostics AS in the lower half of its industry. The industry median EV-to-FCF is 23.36. Gentian Diagnostics AS's value of 45.90 is 96.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.36, based on 416 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gentian Diagnostics AS's current EV-to-FCF of 45.90 is 96.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Gentian Diagnostics AS and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gentian Diagnostics AS's current EV-to-FCF is 45.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (FRA:6FK) is currently considered Significantly Undervalued. The stock's GF Value™ is €5.19, compared to a current price of €3.47 — trading 33.1% below its estimated fair value. The current EV-to-FCF is 45.90 and 96.5% above the Medical Devices & Instruments industry median of 23.36. Gentian Diagnostics AS's overall GF Score™ is 73/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Gentian Diagnostics AS (FRA:6FK), the current EV-to-FCF is 45.90 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gentian Diagnostics AS (FRA:6FK) Overvalued in 2026?
Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued.
The current stock price of €3.47 is trading 33.1% below its estimated GF Value™ of €5.19.
GuruFocus considers Gentian Diagnostics AS to be Significantly Undervalued.
Key valuation signals for FRA:6FK:
EV-to-FCF: 45.90
GF Value™: €5.19 vs. price of €3.47 (33.1% below fair value)
Industry Position: 96.5% above the Medical Devices & Instruments median (#295 of 416)
No single metric tells the full story. See the FRA:6FK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
73GF Score
Get the complete analysis for FRA:6FK
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6FK has been successfully added to your 
